Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full News1.
TKI Discontinuation Feasible After ALL Treatment
2.
Breast cancer: Why it's difficult to treat and what new approaches are on the horizon
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Triplet Could Become a New Standard in Tough-to-Treat CLL
5.
November 2023, Medical Bulletin 04/.
1.
Digital Blood Cell Morphology Libraries for Longitudinal Hematologic Monitoring
2.
Screening for Occult Platelet Dysfunction: Mechanisms, Clinical Implications, and Evidence-Based Approaches
3.
Emerging Therapies Using Tumor-Activated Prodrug Systems for Selective Cancer Cell Killing
4.
Screening for Early Therapy-Related Cancer Susceptibility
5.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
2.
Comprehensive Update on Hematology
3.
Current Scenario of Cancer- Q&A Session to Close the Gap
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge